AACC uses Cookies to ensure the best website experience. Continuing without changing Cookie settings assumes you consent to our use of cookies on this device. You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy policy

AACC International CPOCT Online Program

The Latest Point-of-Care Technologies: Preparing for an Era of Change

Program Outline

Introduction

  Opening/Welcome Remarks
L.V. Rao, PhD, FAACC (Planning Committee Chair), Quest Diagnostics-North Region

Session 1: Advances in POCT

 

Emerging Microfluidics-Based Point-of-Care Technologies for Infectious Diseases and Beyond 
Moderator: Nichole Korpi-Steiner, PhD, DABCC, FAACC, University of North Carolina
Speaker: Ping Wang, PhD, DABCC, FAACC, University of Pennsylvania Perelman School of Medicine
There are several emerging infectious diseases with various threats to humans. As these diseases evolve, so does technologies used in infectious disease POCT, specifically the use of microfluidics in POCT. In this presentation, different examples of microfluidic technologies in infectious disease diagnostics, grouped based on the type of analytes they target, and for each analyte type, technology examples deployed in the SARS-CoV-2 pandemic will be reviewed. Learn of a novel technology called Microbubbling Digital Assay developed for ultrasensitive biomarker quantitation, including for the SARS-CoV-2 antigen.

Lab-on-a-chip System Development for Chronic Disease Diagnosis (CKD and COPD Assessment)
Moderator: Nicolas Tetreault, PhD, CSPQ, FCACB, Biron Health Group
Speaker: Francis Lin, PhD, University of Manitoba
Timely and accurate medical assessments are important for the management of various chronic diseases.  Emerging lab-on-chip technologies (LOC) offer a promising approach for chronic disease evaluation at point-of-care (POC). In this presentation, recent development of LOC-based chronic disease POC diagnosis applications will be introduced with a focus on chronic respiratory disease and chronic kidney disease. Selected examples will be discussed, and future directions will be highlighted. 

Machine Learning Enhanced Point-of-Care Testing: The Promise and Potential Pitfalls of Artificial Intelligence 
Moderator: Peggy Mann, MS, MT(ASCP), CPP, University of Texas Medical Branch
Speaker: Nam K. Tran, PhD, HCLD (ABB), FACB, UC Davis School of Medicine
Artificial intelligence (AI) and machine learning (ML) techniques is poised to transform healthcare delivery over the coming years. The use of AI/ML in laboratory medicine is growing with emerging opportunities in point-of-care (POC) testing. This presentation provides an overview of common AI/ML techniques, best practices, promises and pitfalls, as well as real world applications. Specifically, we will discuss the performance of AI/ML methods for predicting sepsis and acute kidney injury, as well as the use of AI/ML with POC testing. 

Recorded Q&A Segment with Faculty: Advances in POCT

SESSION 2: On the Horizon of POCT

 

Clinical Lab 2.0: How the Laboratory Can Support Value Based Care, Optimize Patient Outcomes, and Reduce Total Costs of Care
Moderator: Sean Cunningham, PhD, EuSpLM, Retired
Speaker: David G. Grenache, PhD, D(ABCC), TriCore Reference Laboratory; University of New Mexico
As healthcare transitions to value-based models, the business strategy for laboratory medicine needs to be reevaluated in terms of clinical and economic valuation; commonly called “Clinical Lab 2.0.” Laboratory professionals must challenge the perceptions of the clinical laboratory as merely a provider of test results to that of a provider of integrated and actionable clinical insights. These insights can decrease the total cost of care and improve patient outcomes through the movement from sick care to well care. This presentation will demonstrate that leveraging historical and longitudinal test results to develop targeted population health management tools that are integrated into clinical workflows can lead to improved patient outcomes and reduced total cost of care.

Point-of-care Molecular Testing: Multiplex Nucleic Acid Amplification Panels for Infectious Diseases. What’s Out There Now and What’s the Evidence Supporting Clinical Utility? 
Moderator: Lilah Evans, MT(ASCP), CPP, Thomas Jefferson University Hospital
Speaker: Robin Patel, MD(CM), D(ABMM), FIDSA, FACP, F(AAM), Mayo Clinic
In this presentation, an overview of multiplex nucleic acid amplification panels for infectious diseases, including point-of-care options will be provided. Several multiplex panels will be covered, including those for testing for gastrointestinal pathogens, meningitis/encephalitis, and respiratory tract and bloodstream infections. Importance on patient (and parent) specimen collection will be reviewed.

Perks and Pitfalls of Point-of-Care Drug Testing 
Moderator: Danyel Tacker, PhD, DABCC, FAACC, West Virginia University Hospital
Speaker: Sarah Delaney, PhD, St. Michael’s Hospital – Unity Health Toronto
The misuse and abuse of opioids remains a serious public health issue across North America. This session will describe the importance of urine drug testing in pain management and identify the role of point-of-care in supporting controlled substance monitoring. The advantages and challenges associated with point-of-care drug testing devices will be discussed.

Recorded Q&A segment with faculty: On the Horizon of POCT

CLOSING

  CLOSING REMARKS
L.V. Rao, PhD, FAACC (Planning Committee Chair), Quest Diagnostics-North Region